Medicare Covers The Majority Of FDA-Approved Devices And Part B Drugs, But Restrictions And Discrepancies Remain

Chambers, James D.; May, Katherine E.; Neumann, Peter J.
June 2013
Health Affairs;Jun2013, Vol. 32 Issue 6, p1109
Academic Journal
The Food and Drug Administration (FDA) and Medicare use different standards to determine, first, whether a new drug or medical device can be marketed to the public and, second, if the federal health insurance program will pay for use of the drug or device. This discrepancy creates hurdles and uncertainty for drug and device manufacturers. We analyzed discrepancies between FDA approval and Medicare national coverage determinations for sixty-nine devices and Part B drugs approved during 1999-2011. We found that Medicare covered FDA-approved drugs or devices 80 percent of the time. However, Medicare often added conditions beyond FDA approval, particularly for devices and most often restricting coverage to patients with the most severe disease. In some instances, Medicare was less restrictive than the FDA. Our findings highlight the importance for drug and device makers of anticipating Medicare's needs when conducting clinical studies to support their products. Our findings also provide important insights for the FDA's and Medicare's pilot parallel review program


Related Articles

  • CMS can still order trials before full coverage. Dickson, Virgil // Modern Healthcare;1/26/2015, Vol. 45 Issue 4, p0014 

    The article reports that U.S Center for Medicare & Medicaid Services can order drug and device manufacturer to collect evidence on the working of their technology before providing approval for reimbursement. It reveals that CMS uses its coverage-with-evidence-development policy to make coverage...

  • Private Payers Disagree With Medicare Over Medicai Device Coverage About Half The Time. Chambers, James D.; Chenoweth, Matthew; Thorat, Teja; Neumann, Peter J. // Health Affairs;Aug2015, Vol. 34 Issue 8, p1376 

    There are multiple payers in the US health care system, each making its own coverage determinations for medical technologies. For each of the forty-seven medical devices considered in national coverage determinations (NCDs) of the Centers for Medicare and Medicaid Services (CMS) issued between...

  • NEWSLINE.  // MPR - Physician Assistants' Edition;Fall2014, Vol. 21 Issue 3, pA12 

    The article provides updates on the U.S. pharmaceutical industry as of September 2014. Topics discussed include the approval of Sivextro oxazolidinone agent for the treatment of adults with acute bacterial skin and skin structure infections, the launch of Sitavig in the U.S. by BioAlliance...

  • Medical Device Forum: cGMPS for Combination Products: 21 CFR Part 4-Final Rule. Lincoln, John E. // Journal of Validation Technology;Mar2013, Vol. 19 Issue 1, p1 

    The article reports on the release of Code of Federal Regulations Title 21 Part 4, Current Good Manufacturing Practice (cGMP) Requirements for Combination Products, on January 22, 2013 by the U.S. Food and Drug Administration. The author comments that under this rule, existing cGMPs are being...

  • FDA’s Hamburg to leave office in March. Demko, Paul // Modern Healthcare;2/9/2015, Vol. 45 Issue 6, p0002 

    The article announces that commissioner of the U.S. agency Food and Drug Administration (FDA) Margaret Hamburg will resign from her post in March 2015.

  • Industry Pipeline.  // Ocular Surgery News;3/25/2013, Vol. 31 Issue 6, p50 

    This section offers news briefs on ophthalmology. Second Sight Medical Products has received the U.S. Food and Drug Administration's (FDA) approval for its Argus II retinal prosthesis system to treat patients with retinitis pigmentosa. Bausch + Lomb has received the FDA's 510(k) clearance for...

  • House overwhelmingly passes 21st Century Cures Act. Johnson, Steven Ross // Modern Healthcare;7/13/2015, Vol. 45 Issue 28, p0002 

    The article reports that the U.S. Congress has passed the 21st Century Cures Act. The Act will provide an additional 9.3 billion U.S. dollars to fund the National Institutes of Health for establishing a Cures Innovation Fund to help breakthroughs in biomedical research. The legislation has...

  • Ophthalmic innovations affected by FDA, Patient Protection and Affordable Care Act. Biro, Ashley // Ocular Surgery News;1/25/2013, Vol. 31 Issue 2, p40 

    The article presents various views of leaders about business, and regulatory issues of Food and Drug Administration at the Ophthalmology Innovation Summit. Jim Mazzo, president of Abbott medical Optics said that increasing disruption is causing by FDA delays. Richard Lindstrom, MD OSN Chief...

  • FDA’s Bad Ad Program lacks teeth. Rice, Sabriya // Modern Healthcare;8/24/2015, Vol. 45 Issue 34, p0011 

    The article discusses the Bad Ad Program related to advertisement, citing complaints received by the program following an advertisement of a drug, which features actress Kim Kardashian, as of August 2015. It states that according to the complaint Kardashian did not mentions any side effects of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics